<DOC>
	<DOCNO>NCT00423306</DOCNO>
	<brief_summary>The study safety new organic arsenic compound treatment advance hepatocellular carcinoma</brief_summary>
	<brief_title>A Phase-II Trial ZIO 101 Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Inclusion Criteria 1 . HCC diagnose histology clinical evidence support liver mass ( es ) least 2cm long diameter AFP equal 500 ng/mL cirrhosis chronic HBV HCV infection27 . 2 . Male female patient ≥ 18 year age 3 . Patients life expectancy least 12 week 4 . Patients least one unidimensional measurable lesion CTscan MRI accord Response Evaluation Criteria Solid Tumors ( RECIST ) . 5 . Patients Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 ( see Appendix 4 ) . 6 . Patients receive local therapy , surgery , radiation therapy , hepatic arterial embolization , chemoembolization , radiofrequency ablation cryoablation eligible , provide either target lesion subject local therapy and/or target lesion ( ) within field local therapy show increase ≥ 25 % size . Furthermore , local therapy apply target nontarget lesion need complete least 8 week prior study inclusion . Lesions treat external beam radiation therapy acceptable target lesion , unless fulfil condition describe . 7 . No one prior chemotherapy base regimen allow . Patients receive two regime target therapy use ( washout ) 8 . Cirrhotic status ChildPugh Class A B ( Appendix 5 ) . 9 . Adequate hepatic function screen assess follow : Platelet count ≥ 60 x 109/L Hemoglobin ≥ 8.5 g/dl Total bilirubin ≤ 3 mg/dl ALT AST ≤ 5 x upper limit normal Serum creatinine ≤ 2.0 x upper limit normal PTINR ≤ 2.3 PT ≤ 6 second control 10 . Patients give write informed consent prior study specific screen procedure understand patient right withdraw study time , without prejudice . Exclusion Criteria 1 . Previous malignancy ( except cervical carcinoma situ , adequately treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis T1 ] malignancy curatively treat &gt; 2 year prior entry ) 2 . Congestive heart failure &gt; NYHA Class II 3 . Cardiac arrhythmia require antiarrythmics ( exclude beta blocker digoxin chronic stable atrial fibrillation ) QTc great 450 msec . 4 . Active coronary artery disease cardiac ischemia 5 . Active clinically serious bacterial , viral fungal infection ( &gt; grade 2 NCICTCAE , Version 3 ) 6 . Known history human immunodeficiency virus ( HIV ) infection le 2 year uncontrolled disease antiretroviral medication 7 . Metastatic brain meningeal tumor 8 . Patients seizure disorder require medication ( antiepileptic ) 9 . History confusion dementia neurological condition could mask potential adverse response study drug ( something along line ) 10 . History organ allograft 11 . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result 12 . Known suspected allergy investigational agent agent give association trial 13 . Any condition unstable could jeopardize safety patient his/her compliance study 14 . Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within 14 day prior start study drug . Both men woman enrol trial must use adequate barrier birth control measure course trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>